导语： 在阿尔茨海默病治疗遭遇瓶颈的当下，一款已上市的带状疱疹疫苗正引发科学界的新期待。英国制药巨头葛兰素史克（GSK）宣布与英国痴呆研究所（UK DRI）合作，利用 NHS 接种政策调整形成的 “自然实验”，研究其明星疫苗 Shingrix ...

在阿尔茨海默病治疗陷入瓶颈之际，一项意外的发现引发了科学界的广泛关注。英国制药巨头葛兰素史克（GSK）宣布与英国痴呆研究所（UKDRI）合作，正在研究其明星疫苗Shingrix是否具备降低痴呆症风险的潜力。这一看似偶然的研究，有望为全球疫苗及神经退行性疾病的治疗打开新的思路。

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

（原标题：适应症有望扩大？葛兰素史克(GSK.US)正研究带状疱疹疫苗Shingrix能否降低痴呆风险） 智通财经APP获悉，葛兰素史克(GSK.US)正在英国对一大群 ...

葛兰素史克(GSK.US)正在英国对一大群老年人进行研究，以确定其畅销的带状疱疹疫苗Shingrix是否能降低患痴呆症的风险。这可能为扩大该疫苗的适应症 ...

The study will analyse electronic health records of 65- and 66-year olds from the UK’s National Health Service (NHS).

After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...

GSK partners with UK research groups to study if Shingrix shingles vaccine reduces dementia risk, analyzing NHS data from ...

GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...

GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the ...

GSK, led by boss Emma Walmsley (pictured), is using the data of 1.4m adults aged 65 and 66 to examine the impact of its ...